Pfizer announced Tuesday that its maternal RSV vaccine, given during pregnancy, protected infants from developing severe symptoms during the first six months after birth — a critical window of vulnerability.
The company plans to apply for approval of the vaccine before year’s end, with the hope that the shot could be the first vaccine to help protect infants against RSV — respiratory syncytial virus — as soon as next winter.
The data was announced in a news release and has not yet been published or peer reviewed. But it offers a glimmer of good news in the middle of a brutal and early RSV season that has contributed to a wave of respiratory illness that is overwhelming many paediatric hospitals.
Read on Washington Post
